The role of cholecalciferol in the pathogenesis of polycystic ovary syndrome

Abstract

Objective — to evaluate and compare clinical, anamnestic and laboratory data of patients with polycystic ovary syndrome (PCOS) and without syndrome, including the level of vitamin 25(OH) D₃.

Material and methods. In this work, 81 patients were examined, who, at the 1st stage of the study, were divided into two groups depending on the presence or absence of signs of PCOS. The main group included 51 patients with signs of PCOS. The control group included 30 healthy women without signs of PCOS, matched by sex and age with the main group. The main and control groups were compared by clinical and anamnestic data, including birth weight, by the presence of complications of pregnancy and childbirth in their mothers during their gestation, by the level of vitamin D. PCOS was verified on the basis of diagnostic criteria Rotterdam (2003) and International guidelines on PCOS (2018). Vitamin 25(OH)D₃ was determined by mass spectrometry (ng/ml).

At the 2nd stage of the study, the main group with PCOS was divided into 2 subgroups depending on the waist circumference (WT). Subsequently, the subgroups were compared with each other in the same parameters as at stage 1, as well as in the level of insulin, low-density lipoprotein (LDL), triglycerides (TG), anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). To reflect the statistical results, the parametric parameters of the Student’s t-test were applied for two independent samples with equal or different variance. For nominal data — Pearson’s Chi-test, when the means are not calculated and a test is carried out for the presence of a relationship between nominal variables.

Results. There was no statistically significant difference in vitamin 25(OH)D₃ levels in patients with and without PCOS. Statistically significant differences in vitamin 25(OH)D₃ levels were found in women with PCOS, depending on the waist circumference (WT). In these subgroups, differences were also found in the level of insulin, LDL, TG.

Conclusion. The values of the level of vitamin 25(OH)D₃ do not differ in the groups of patients with PCOS and without PCOS, but significantly correlate with the metabolic profile of patients.

Keywords

vitamin D / polycystic ovary syndrome / insulin / waist circumference

References

[1] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic Ovary Syndrome (PCOS). Hum Reprod. 2004;(19):41‒47. doi: 10.1093/humrep/deh098

[2] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic Ovary Syndrome (PCOS) // Hum Reprod. 2004. N 19. Р. 41‒47. https://doi.org/10.1093/humrep/deh098

[3] Shilin DE. Polycystic ovary syndrome: international diagnostic consensus and current ideology of IL therapy. Farmateka. 2004;(12):12‒19. (In Russ).

[4] Шилин Д.Е. Синдром поликистозных яичников: Международный диагностический консенсус и современная идеология терапии IL // Фарматека. 2004. № 12 . С. 12‒19.

[5] Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24(3):302‒312. doi: 10.1210/er.2003-0004

[6] Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association? // Endocrin Rev. 2003. Vol. 24. N 3. P. 302‒312.

[7] Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Human Reprod. 2002;17(9):2219‒2227. doi: 10.1093/humrep/17.9.2219

[8] Balen A., Michelmore K. What is polycystic ovary syndrome? Are national views important? // Human Reprod. 2002. Vol. 17. N 9. P. 2219‒2227.

[9] Prilepskaya VN. Obesity in the practice of an obstetrician-gynecologist (clinical lecture). Akusherstvo i ginekologiya. 2003;(6):59‒61. (In Russ).

[10] Прилепская В.Н. Ожирение в практике акушера-гинеколога (клиническая лекция) // Акушерство и гинекология. 2003. № 6. С. 59‒61.

[11] Pasquali R, et al. Obesity and reproductive disorders in women. Human Reprod. 2003;9(4):359‒372. doi: 10.1093/humupd/dmg024

[12] Pasquali R, et al. Obesity and reproductive disorders in women // Human Reprod. 2003. Vol. 9. N 4. P. 359‒372. doi: 10.1093/humupd/dmg024

[13] De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14:38. doi: 10.1186/s12958-016-0173-x

[14] De Leo V., Musacchio M.C., Cappelli V., Massaro M.G., Morgante G., Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update // Reprod Biol Endocrinol. 2016. Vol.14. P. 38. doi: 10.1186/s12958-016-0173-x

[15] Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - Part 2. Endocr Pract. 2015;21:1415‒1426. doi: 10.4158/EP15748.DSCPT2

[16] Goodman N.F., Cobin R.H., Futterweit W., Glueck J.S., Legro R.S., Carmina E.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2 // Endocr. Pract. 2015. Vol. 21. P. 1415‒1426. doi: 10.4158/EP15748.DSCPT2

[17] Moran L, Misso M, Wild R, Norman R. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and metaanalysis. Hum Reprod Update. 2010;16(4):347‒363. doi: 10.1093/humupd/dmq001

[18] Moran L., Misso M., Wild R., Norman R. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and metaanalysis // Hum Reprod Update. 2010. Vol. 16. N 4. P. 347‒363.

[19] Paffoni A, Ferrari S, Viganò P, et al. Vitamin D deficiency and infertility: insights from in vitro fertilization cycles. J Clin Endocrinol Metab. 2014;99(11):E2372‒E2376. doi: 10.1210/jc.2014-1802

[20] Paffoni A., Ferrari S., Viganò P., et al. Vitamin D deficiency and infertility: insights from in vitro fertilization cycles // J Clin Endocrinol Metab. 2014. Vol. 99. N 11. P. E2372‒E2376. doi: 10.1210/jc.2014-1802

[21] Moini A, Shirzad N, Ahmadzadeh M, Hosseini R, Hosseini L, Sadatmahalleh S. Comparison of 25-hydroxyvitamin D and calcium levels between polycystic ovarian syndrome and normal women. Int J Fertil Steril. 2015;9(1):1‒8. doi: 10.22074/ijfs.2015.4201

[22] Moini A., Shirzad N., Ahmadzadeh M., Hosseini R., Hosseini L., Sadatmahalleh S. Comparison of 25-hydroxyvitamin D and calcium levels between polycystic ovarian syndrome and normal women // Int J Fertil Steril. 2015. Vol. 9. N 1. P. 1‒8. doi: 10.22074/ijfs.2015.4201

[23] Kim JJ, Choi YM, Chae SJ, et al. Vitamin D deficiency in women with polycystic ovary syndrome. Fertil Steril. 2013;99(6):1779‒1785.

[24] Kim J.J., Choi Y.M., Chae S.J., et al. Vitamin D deficiency in women with polycystic ovary syndrome // Fertil Steril. 2013. Vol. 99. N 6. P. 1779‒1785.

[25] Figurová J, Dravecká I, Javorský M, Petríková J, Lazúrová I. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome andits relation to metabolic and reproductive abnormalities. Wien Klein Wochenschr. 2016;128(17-18):641‒648. doi: 10.1007/s00508-015-0768-9

[26] Figurová J., Dravecká I., Javorský M., Petríková J., Lazúrová I. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome andits relation to metabolic and reproductive abnormalities // Wien Klein Wochenschr. 2016. Vol. 128. N 17-18. P. 641‒648. doi: 10.1007/s00508-015-0768-9

[27] Kuznetsova IV. The role of insulin sensitizers and calcium supplements with vitamin D3 in the complex therapy of polycystic ovary syndrome. Problemy endokrinologii. 2013;(1):49‒56. (In Russ).

[28] Кузнецова И.В. Роль инсулиносенситайзеров и препаратов кальция с витамином D3 в комплексной терапии синдрома поликистозных яичников // Проблемы эндокринологии. 2013. № 1. С. 49‒56.

[29] Faraji R, Sharami SH, Zahiri Z, Asgharni M, Kazemnejad E, Sadeghi S. Evaluation of relation between anthropometric indices and vitamin D concentrations in women with polycystic ovarian syndrome. J Family Reprod Health. 2014;8(3):123‒129. PMID: 25628722

[30] Faraji R., Sharami S.H., Zahiri Z., Asgharni M., Kazemnejad E., Sadeghi S. Evaluation of relation between anthropometric indices and vitamin D concentrations in women with polycystic ovarian syndrome // J Family Reprod Health. 2014. Vol. 8. N 3. P. 123‒129. PMID: 25628722

[31] Kozakowski J, Kapuścińska R, Zgliczyński W. Associations of vitamin D concentration with metabolic and hormonal indices in women with polycystic ovary syndrome presenting abdominal and gynoidal type of obesity. Ginekol Pol. 2014;85(10):765‒770.

[32] Kozakowski J., Kapuścińska R., Zgliczyński W. Associations of vitamin D concentration with metabolic and hormonal indices in women with polycystic ovary syndrome presenting abdominal and gynoidal type of obesity // Ginekol Pol. 2014. Vol. 85. N 10. P. 765‒770.

[33] Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. International PCOS Network Author Notes. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reprod. 2018;33(Is 9):1602‒1618. doi: 10.1093/humrep/dey256

[34] Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., et al. International PCOS Network Author Notes. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome // Human Reprod. 2018. Vol. 33. Is. 9. P. 1602‒1618. doi: 10.1093/humrep/dey256

[35] Dedov II, Mel’nichenko GA. Clinical recommendations. Vitamin D Deficiency in Adults: Diagnosis, Treatment, Prevention. Moscow: Russian Association of endocrinologists; 2015. 75 p. (In Russ).

[36] Дедов И.И., Мельниченко Г.А. Клинические рекомендации. Дефицит витамина D у взрослых: диагностика, лечение, профилактика. М. : Российская ассоциация эндокринологов, 2015. 75 с.

RIGHTS & PERMISSIONS

Eco-Vector